HLA-DO is a negative modulator of HLA-DM-mediated MHC class II peptide loading  by van Ham, S.M. et al.
950 Research Paper
HLA-DO is a negative modulator of HLA-DM-mediated MHC
class II peptide loading
S.M. van Ham*, E.P.M. Tjin*, B.F. Lillemeier†, U. Grüneberg†, K.E. van
Meijgaarden‡, L. Pastoors*, D. Verwoerd*, A. Tulp*, B. Canas§, D. Rahman§,
T.H.M. Ottenhoff‡, D.J.C. Pappin§, J. Trowsdale¶ and J. Neefjes*
Background: Class II molecules of the major histocompatibility complex
become loaded with antigenic peptides after dissociation of invariant chain-
derived peptides (CLIP) from the peptide-binding groove. The human leukocyte
antigen (HLA)-DM is a prerequisite for this process, which takes place in
specialised intracellular compartments. HLA-DM catalyses the peptide-
exchange process, simultaneously functioning as a peptide ‘editor’, favouring
the presentation of stably binding peptides. Recently, HLA-DO, an
unconventional class II molecule, has been found associated with HLA-DM in B
cells, yet its function has remained elusive. 
Results: The function of the HLA-DO complex was investigated by expression
of both chains of the HLA-DO heterodimer (either alone or fused to green
fluorescent protein) in human Mel JuSo cells. Expression of HLA-DO resulted in
greatly enhanced surface expression of CLIP via HLA-DR3, the conversion of
class II complexes to the SDS-unstable phenotype and reduced antigen
presentation to T-cell clones. Analysis of peptides eluted from HLA-DR3
demonstrated that CLIP was the major peptide bound to class II in the HLA-
DO transfectants. Peptide exchange assays in vitro revealed that HLA-DO
functions directly at the level of class II peptide loading by inhibiting the
catalytic action of HLA-DM. 
Conclusions: HLA-DO is a negative modulator of HLA-DM. By stably
associating with HLA-DM, the catalytic action of HLA-DM on class II peptide
loading is inhibited. HLA-DO thus affects the peptide repertoire that is
eventually presented to the immune system by MHC class II molecules.
Background
Antigen presentation, a key event in the functioning of
the immune system, is a well-controlled process, regulated
by a number of independent factors. Antigens derived
from exogenous sources, such as pathogenic bacteria, are
presented to the immune system after intracellular degra-
dation and association with class II molecules of the major
histocompatibility complex (MHC) [1]. The association
step occurs in specialised intracellular compartments,
termed MIIC (MHC class II compartments) [2], to which
the class II heterodimers are directed from the endo-
plasmic reticulum (ER) after association with a third
glycoprotein, the invariant chain (Ii) [3]. During transport,
Ii is degraded by proteases like cathepsin S [4], until only
a nested set of peptides, termed CLIP for class II-associ-
ated invariant chain peptides, remains bound to the
peptide-binding groove of the class II molecules [5,6]. 
Although spontaneous exchange of CLIP for antigenic
peptides might occur in the MIICs and is favoured by the
lysosomal-like pH of these compartments [7,8], an addi-
tional factor is essential for this process. Mice or cell lines
carrying a mutation in the genes encoding the het-
erodimer human leukocyte antigen (HLA)-DM are defec-
tive in antigen presentation and express predominantly
class II molecules that still contain CLIP [9–12]. HLA-
DM is localised in the MIICs, where it catalyses peptide
exchange by enhancing the dissociation of CLIP and sta-
bilising the peptide-free state of the class II molecules.
Simultaneously, HLA-DM functions as a peptide ‘editor’
in that its catalytic action promotes dissociation of pep-
tides that do not bind stably to the class II backbone, thus
skewing the peptide repertoire that is eventually
expressed at the cell surface in the direction of stably
binding antigenic peptides [13–21].
Recently, another unconventional MHC molecule, HLA-
DO, has been found tightly associated with HLA-DM in
B cells [22]. HLA-DO, a heterodimeric complex of the
HLA-DOα (formerly termed HLA-DNα or HLA-DZα)
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[23] and HLA-DOβ chains [24], localises to the MIICs
upon association with HLA-DM [22]. In mice lacking
H2-M, the mouse equivalent of HLA-DM, or in human
cell lines bearing a mutation in HLA-DM, HLA-DO
expression is lowered and confined to the ER, demon-
strating that HLA-DO requires HLA-DM association for
efficient egress from the ER ([22]; C. Thomas, C.
Roucard, J.T. and S.M.v.H., unpublished observations).
Although the association between HLA-DM and HLA-
DO might indicate that the functions of both complexes
are linked, the action of HLA-DO has remained as yet
unknown.
The function of HLA-DO was investigated by introduc-
ing HLA-DOαβ or HLA-DOαβ coupled to green fluores-
cent protein (HLA-DOαβ–GFP) [25] into cell lines that
express functional class II and HLA-DM molecules but
lack the expression of HLA-DO molecules. Expression of
either form of HLA-DO markedly increased the amount
of class II molecules at the cell surface that still contained
CLIP and greatly reduced the amount of class II mole-
cules associated with antigenic peptides. Consequently,
HLA-DO expression hampered antigen presentation to T
cells. Peptide-exchange assays in vitro showed that
HLA-DO binding to HLA-DM interfered with class II
peptide exchange by directly inhibiting the catalytic
action of HLA-DM. 
Results and discussion
The function of HLA-DO was explored by transfection of
HLA-DOα [23] and HLA-DOβ [24] cDNA expression
constructs into Mel JuSo cells. These cells stably express
the components needed for antigen presentation by class
II molecules, including Ii, HLA-DM and HLA-DR3 [21],
but no HLA-DO could be detected by immunoblotting
analysis (see later). 
Figure 1
Confocal and western-blot analysis of HLA-DOβ–GFP (DOβ–GFP)
single and HLA-DOαβ–GFP double transfectants. (a) Confocal
analysis demonstrates that the HLA-DOβ–GFP single chain is retained
in the ER. HLA-DOβ–GFP transfectants were fixed with methanol and
stained with an antibody against class II HLA-DRα chain. Fluorescence
from GFP is shown in the left panel, whereas HLA-DRα staining (DRα)
is shown in the right panel. The middle panel is a overlay of the left and
right images. HLA-DOβ–GFP stains the nuclear envelope and a fine
reticular network, whereas class II is seen in perinuclear vesicles that
do not co-localise with HLA-DOβ–GFP. (b) HLA-DOαβ–GFP is
observed in lysosomal vesicles containing HLA-DM and class II upon
confocal analysis. Double transfectants were fixed and stained with
antibodies against HLA-DRα, HLA-DM or CD63, as indicated (DRα,
DMα and CD63, respectively). The left panel is the GFP fluorescence;
the right panel shows the staining for the other proteins, and the
middle panel represents the overlay, with co-localisation shown as
yellow. (c) Cell lysates of HLA-DOαβ–GFP transfectants were
analysed by SDS–PAGE before (total lysate) or after various rounds of
immunoprecipitation with anti-GFP antibodies (lysate 2). The first
immuno-isolate was loaded as well (lane Anti-GFP). Proteins were then
transferred to nitrocellulose and the filter was treated with the anti-
HLA-DMα antibody 5C1. Two closely migrating bands were visualised
in the total lysate, the lower band corresponding to the high-mannose
carbohydrate containing HLA-DMα chain (the ER form) and the higher
band corresponding to the most abundant, complex-carbohydrate-
containing HLA-DMα chain (transported through the Golgi to the
MIIC). The upper band was quantitatively removed by the anti-GFP
isolations, whereas the lower band mostly remained in the lysate
fractions, probably because it was not fully associated with HLA-
DOαβ–GFP in the ER.
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Transfection of an HLA-DOβ–GFP cDNA expression
construct into Mel JuSo cells resulted only in a fine reticu-
lar staining that resembled staining for the ER (Figure 1a):
double-labeling for class II expression revealed that class
II molecules were transported to perinuclear vesicles as
normal and did not co-localise with the free HLA-
DOβ–GFP chain. We next transfected the cells with
cDNA expression vectors for HLA-DOα and HLA-
DOβ–GFP [25], to verify that HLA-DO was expressed in
all cells. Confocal analysis of clones stably expressing
HLA-DOαβ–GFP showed that the HLA-DOαβ–GFP
heterodimer co-localised with HLA-DR3 and HLA-DM
in acidic, CD63-positive MIIC vesicles (Figure 1b).
Apparently, both α and β chains of HLA-DO need to be
expressed for correct intracellular transport. Two-dimen-
sional electrophoretic analysis of immunoprecipitations
with an anti-GFP serum demonstrated the formation of a
complex between HLA-DOβ–GFP and HLA-DOα, and
association of HLA-DO with the HLA-DM complex, con-
sistent with previous findings [22]. In contrast to the
findings in B cells (data not shown), depletion experi-
ments indicated that HLA-DM was quantitatively
associated with HLA-DOαβ–GFP in the Mel JuSo
transfectants (Figure 1c). 
To investigate the differential effects of HLA-DO expres-
sion on peptide presentation by class II molecules, flow
cytometric analyses were performed. Clones expressing
HLA-DOαβ showed a similar expression of HLA-DR3 as
control transfectants, but with greatly enhanced surface
presentation of CLIP (Figure 2a). Fluorescence-activated
cell sorter (FACS) analyses of Mel JuSO cells transfected
with both empty vectors showed low levels of surface
expression of class II-associated CLIP (Figure 2b). In con-
trast, HLA-DOαβ–GFP transfectants showed highly
enhanced CLIP presentation. As the cloned transfectants
lost HLA-DOαβ–GFP expression, they concomitantly lost
CLIP surface expression, which dropped to a level similar
to that found in control transfectants; however, class II
expression levels remained unaffected (Figure 2b). These
findings point to an antagonistic effect of HLA-DO on
release of CLIP from the HLA-DR3 molecule, resulting in
a similar phenotype as in HLA-DM-negative cells [26,27]. 
Stability of complexes in SDS can be used as to measure
the level of binding of antigenic peptides, but not of
CLIP, to HLA-DR3 molecules [27]. When compared with
control cells, a FACS-sorted, HLA-DOαβ–GFP-positive
population showed a large reduction in the amount of
SDS-stable HLA-DR3 complexes by western-blot analy-
ses, with the total level of HLA-DR3 expression remain-
ing unchanged (Figure 3a). This reduction did not result
from a decreased level of HLA-DM expression in the
HLA-DOαβ–GFP transfectants (Figure 3a). The amount
of SDS-stable class II complexes was also greatly reduced
in the HLA-DOαβ transfectant (Figure 3b), indicating
that the GFP tag did not adversely affect the function of
HLA-DO, as also seen in Figure 2. 
The effect of HLA-DO expression was examined further
by comparison of peptides eluted from HLA-DR3 mole-
cules that had been affinity-purified from FACS-sorted,
HLA-DOαβ–GFP transfectants with peptides obtained in
a similar way from HLA-DO-negative cells. The HPLC
(high pressure liquid chromatography) profile of the eluted
Figure 2
Expression of the HLA-DO complex in Mel JuSo cells enhances cell-
surface expression of HLA-DR3-associated CLIP. (a) FACS analysis of
5,000 cloned Mel JuSo cells transfected with vectors only (DOαβ–) or
HLA-DOαβ (DOαβ+) showing background staining using secondary
PE-conjugated antibodies only (dotted lines), class II-specific staining
using monoclonal antibody L243 [40] and CLIP-specific staining using
CerCLIP.1 [41]. Histogram staining profiles of live gated cells are
shown. (b) FACS analysis of cloned transfectants with vectors only
(DOαβ–GFP–) or HLA-DOαβ–GFP (DOαβ–GFP+) showing
background staining only (–), class II-specific or CLIP-specific staining.
The vertical axis represents GFP fluorescence and the horizontal axis
represents phycoerythrin (PE) fluorescence, each in arbitrary units on a
logarithmic scale.
class II peptides was clearly altered upon HLA-
DOαβ–GFP expression, with the appearance of a set of
peaks eluting with 30–35% acetonitrile (Figure 4a). This
set of peaks strongly resembled the HPLC pattern
observed for HLA-DM-negative cells [26,27]. Analysis of
the peptide content of these peaks by matrix-assisted laser
desorption (MALD) time-of-flight mass spectrometry
(MS) [28] identified peptides of 21–24 residues in length,
that were present in relatively high amounts (Figure 4b).
The peptide masses corresponded to three CLIP variants
[26,27]. This finding was confirmed by digesting the pep-
tides with trypsin, derivatisation with SPA (n-succinimidyl-
2 (3-pyridyl) acetate) and sequencing of the
carboxy-terminal tryptic fragments by low-energy collision-
induced dissociation (CID) tandem MS (Figure 4b)
[29,30]. In the corresponding fractions in the HLA-DO-
negative control, only minute amounts of these CLIP pep-
tides could be detected (Figure 4b), with the concomitant
appearance of small amounts of numerous other peptides.
In the HLA-DOαβ–GFP transfectant, other peptides
besides CLIP peptides were also detected, but in much
lower amounts and mainly of different masses than the
peptides detected in the control transfectant, consistent
with the observation that HLA-DO expression reduces,
but does not abolish formation of SDS-stable class II com-
plexes. Together, these data suggest that the majority of
HLA-DR3 molecules are complexed to CLIP upon quan-
titative association of HLA-DOαβ–GFP and HLA-DM.
We next addressed the question of the mode of action by
which HLA-DO influences class II peptide presentation.
Expression of HLA-DO did not alter the intracellular dis-
tribution of HLA-DM and class II molecules (as deter-
mined by subcellular fractionation experiments), nor did it
change the maturation rate of SDS-stable class II com-
plexes (data not shown). Peptide association and dissocia-
tion studies in vitro were performed on HLA-DR3–CLIP
molecules isolated from T2.DR3 cells [31] using cell
lysates from FACS-sorted HLA-DOαβ–GFP-expressing
cells or control transfectants. Addition of lysates containing
HLA-DM without HLA-DO catalysed the dissociation of
the biotinylated full-length CLIP(81–104) peptide [32]
from HLA-DR3 molecules, but not of the stably bound
ApoB(2877–2894) peptide [32] (Figure 5a), in agreement
with previous findings [16]. Addition of lysates from trans-
fectants expressing HLA-DO were catalytically defective
for CLIP(81–104) dissociation, despite containing similar
quantities of HLA-DM as control transfectants. Moreover,
whereas HLA-DM lysates greatly enhanced exchange of
free biotinylated CLIP(81–104) or ApoB(2877–2894) pep-
tides on purified HLA-DR3–CLIP complexes, this cat-
alytic effect was greatly reduced by addition of
HLA-DO–HLA-DM lysates (Figure 5b). These experi-
ments were repeated with lysates from purified MIIC com-
partments containing equal amounts of HLA-DM and
HLA-DM–HLA-DO complexes (Figure 5c, inset). These
results demonstrated that HLA-DM–HLA-DO complexes
from MIICs were 70–80% less efficient in the formation of
HLA-DR3–ApoB(2877–2894) complexes than were the
HLA-DM complexes alone (Figure 5c). We tentatively
conclude that HLA-DO affects class II peptide presenta-
tion by acting directly as a negative modulator of the chap-
erone HLA-DM, resulting in an increase in CLIP bound to
HLA-DR3 and reduced stability of class II molecules.
If HLA-DO association to HLA-DM is negatively
modulating HLA-DM action, presentation of antigen to
proliferative T cells should be reduced as well. The 
antigen-presenting capacities of control and HLA-
DOαβ–GFP-expressing Mel JuSo cells were assessed
by pulsing the cells with recombinant hsp65 protein of
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Figure 3
Reduction of amount of SDS-stable HLA-DR3 complexes upon HLA-
DO expression. (a,b) Immunoblotting of whole cell lysates of 1 × 106
Mel JuSo cells transfected with vectors only (–) or with HLA-
DOαβ–GFP (DOαβ–GFP) or HLA-DOαβ (DOαβ), followed by
detection of the total amount of HLA-DMα (DMα), HLA-DOβ–GFP
(DOβ–GFP) and SDS-stable HLA-DR3α (DR3α) complexes. The
HLA-DR3α and HLA-DR3β chains of SDS-stable HLA-DR3 dimers
remain associated in SDS-containing sample buffer under non-boiling
(nb) conditions, but dissociate upon boiling (b) conditions. Arrowheads
indicate the position of the HLA-DR3αβ dimers (αβ) or DR3α
monomer (α). HLA-DMα and HLA-DOβ–GFP were detected upon
boiling of the samples. The position of the HLA-DOβ–GFP protein is
indicated, with additional bands representing HLA-DO-unrelated,
cross-reactive species. Molecular sizes are indicated on the left (in
kDa). For detection of HLA-DMα, the HLA-DMα-specific monoclonal
antibody 5C1 [34] was used and HLA-DR3 complexes were detected
using the HLA-DR3α-specific monoclonal antibody 1B5 [42].
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Mycobacterium tuberculosis and subsequently using them to
stimulate T cells in a proliferation assay using an HLA-
DR3-restricted T-cell clone recognising hsp65 epitope
p3–13 [33]. Although both control cells and HLA-
DOαβ–GFP-expressing cells were able to present the p3–13
epitope of intact hsp65 specifically, HLA-DOαβ–GFP
expression clearly reduced the antigen-presenting capacity
of the cells (Figure 6). No significant proliferative response
was detected in response to unpulsed cells. 
To our knowledge, HLA-DO is the first protein that has
been identified to function as an inhibitor of a chaperone
(HLA-DM). To fully appreciate the effect of HLA-DO on
HLA-DM-mediated class II peptide loading, we have
generated cells in which HLA-DM shows quantitative
association with HLA-DO. Even under these conditions,
class II peptide loading is not completely abolished; part
of the class II molecules still succeed in binding antigenic
peptides, as demonstrated by the residual amount of
SDS-stable class II complexes and the diminished, but
still significant, antigen-presenting capacity of HLA-
DOαβ–GFP-expressing transfectants. Thus, instead of
blocking HLA-DM action, the association of HLA-DO
with HLA-DM is down-modulating HLA-DM-mediated
class II peptide presentation. The observation that HLA-
DO expression seems to be restricted to certain
specialised antigen-presenting cells [22,34] as well as to
distinct regions of the thymus [34] suggests that HLA-DO
may affect the peptide repertoire presented by class II
molecules only in particular situations. In B cells, part of
HLA-DM is associated with HLA-DO which would result
only in partial down-modulation of HLA-DM-mediated
class II peptide loading. Primary B cells may require
optimal peptide loading onto class II molecules only upon
uptake of antigen via the B-cell receptor. Although there
is no evidence as yet for free HLA-DO molecules outside
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Figure 4
Expression of HLA-DOαβ–GFP changes the
peptide repertoire that is bound to HLA-DR3.
(a) HPLC profiles of acid-eluted peptides
from HLA-DOαβ–GFP-positive cells
(DOαβ–GFP) and cells transfected with
vectors only (DO–). The absorbance of
specific eluate fractions at 214 nm is shown
against their retention time after start of the
gradient. The peaks labelled F1–3 for HLA-
DOαβ–GFP correspond to peaks labelled
F4–6 respectively for HLA-DO–. (b) Analysis
of fractions F1–6 by MALD time-of-flight MS,
together with identified masses and amino
acid sequences of major HLA-DOαβ–GFP
peptides. The relative intensities of CLIPs may
be assessed by comparison to the 100 fmol
peak of [Glu] fibrinopeptide B (indicated by
the asterisk), added as an internal mass
calibrant. The underlined regions of sequence
shown for F1–3 were fully sequenced by low-
energy tandem MS. The arrows indicate the
position of the almost absent corresponding
peptide in HLA-DO– samples.
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the ER, it may be possible that HLA-DO is released from
HLA-DM upon triggering of the B-cell receptor or
down-regulated to shift the peptide-presentation reper-
toire in particular circumstances, an issue that is currently
under study. 
Conclusions
HLA-DO is a negative modulator of HLA-DM, the cata-
lyst of antigen presentation via MHC class II molecules.
Mel JuSo cells expressing the HLA-DOαβ heterodimer
show inhibition of HLA-DM-mediated CLIP release from
the class II molecules. This inhibition results in a pro-
foundly diminished formation of class II–antigenic
peptide complexes and consequently a reduced capacity
to present antigens to T-cell clones. Thus, antigen presen-
tation by MHC class II molecules is a more tightly con-
trolled process than had been anticipated;  HLA-DM
alone skews the expressed peptide repertoire in the direc-
tion of stably binding antigens, whereas association of
HLA-DO with HLA-DM counteracts this ushering mech-
anism. The balance of HLA-DO and HLA-DM expres-
sion in particular circumstances may therefore determine
which antigens will be expressed for the generation of a
specific immune response.
Materials and methods
Construction, characterisation and culture of HLA-DO–GFP
transfectants
The cDNAs encoding HLA-DOβ [24] and HLA-DOα [23] were cloned
into pcDNA3 (Invitrogen) and a variant of pCEP4 (Invitrogen) that is dis-
abled for episomal replication, respectively. A fusion construct of a
FACS-optimised mutant of GFP to the carboxyl terminus of HLA-DOβ
was generated by PCR; the HLA-DOβ cDNA was amplified using a
primer overlapping the HLA-DOβ start codon and a primer specific for
the last eight HLA-DOβ codons, omitting the stop codon but including a
3′ extension specific to the first four codons of GFP. The GFP cDNA
was amplified using a primer specific to the first eight codons of GFP,
with a 5′ extension specific to the last four codons of HLA-DOβ, and a
primer specific to the last seven GFP codons. The resulting products
were used as templates for a subsequent PCR using the primers spe-
cific to the amino terminus of HLA-DOβ and the carboxyl terminus of
GFP. The final construct was checked by sequence analysis and cloned
into pcDNA3. The melanoma cell line Mel JuSO (HLA-A1, HLA-B8,
HLA-Cw7, HLA-DR3 and HLA-DQ2 as determined by DNA typing) was
transfected using the calcium-phosphate precipitation procedure.
Transfectants were selected in Iscove’s medium with 10% FCS,
2000 µg/ml G418 and 600 µg/ml hygromycin (Gibco BRL). HLA-
DOαβ–GFP positive clones were identified by confocal analysis [35]
Research Paper  HLA-DO is negative modulator of HLA-DM van Ham et al. 955
Figure 5
0.0
0.2
0.4
0.6
0.8
R
el
at
iv
e 
ab
so
rb
an
ce
 
(a
rb
itr
ar
y 
un
its
)
DM DO/DM
DM DO/DM Buffer
0.0 0.5 1.0 1.5 2.0
CLIP(81–104)
100
75
50
25
0
D
R
3–
pe
pt
id
e
co
m
pl
ex
es
 (%
)
Incubation time (h)
0.0 0.5 1.0 1.5 2.0
ApoB(2877–2894)
100
75
50
25
0
D
R
3–
pe
pt
id
e
co
m
pl
ex
es
 (%
)
Incubation time (h)
(a) (c)
0.0 0.5 1.0 1.5 2.0
CLIP(81–104)
0.4
0.3
0.2
0.1
0A
bs
or
ba
nc
e 
40
5 
nm

(a
rb
itr
ar
y 
un
its
)
Incubation time (h)
0.0 0.5 1.0 1.5 2.0
ApoB(2877–2894)
0.5
0.4
0.2
0.3
0.1
0A
bs
or
ba
nc
e 
40
5 
nm

(a
rb
itr
ar
y 
un
its
)
Incubation time (h)
(b)
Current Biology
Association of HLA-DO with HLA-DM abolishes HLA-DM-mediated
catalysis of class II peptide loading. (a) Time course of dissociation of
biotinylated CLIP(81–104) and ApoB(2877–2894) from purified HLA-
DR3 molecules in the presence of lysis buffer (dots), cell lysates
containing equal amounts of HLA-DM (squares) or HLA-DO–HLA-DM
(triangles). Dissociation is shown as relative values compared to the
initial amount of HLA-DR3–peptide complexes. (b) Time course of
association of biotinylated CLIP(81–104) and ApoB(2877–2894) with
HLA-DR3–CLIP in the presence of lysis buffer (dots), cell lysates
containing equal amounts of HLA-DM (squares) or HLA-DO–HLA-DM
(triangles). Association is shown as increase in absorbance (405 nm)
in arbitrary units. (c) Association of biotinylated ApoB(2877–2894) to
HLA-DR3–CLIP after 50 min incubation with lysosomal lysates
containing HLA-DM or HLA-DO–HLA-DM or lysis buffer only as
indicated. Association is depicted as absolute values in absorbance at
405 nm (in arbitrary units). Inset: western blot using the HLA-DMα-
specific monoclonal antibody 5C1 [34], demonstrating the presence of
equal amounts of HLA-DM in the applied HLA-DM and HLA-DM–HLA-
DO lysates. The data shown are a representative set of values from
3–4 individual experiments. Titration of added lysates to the
experiments showed that the inhibition of HLA-DM activity correlated
with the amount of lysate added (data not shown).
and two-dimensional electrophoretic analysis of immunoprecipitations
using an anti-GFP antiserum. HLA-DOαβ positive clones were identified
by a rabbit antiserum raised against the carboxy-terminal peptide of HLA-
DOβ (SGNEVSRAVLLPQSC) and by western-blot analysis for expres-
sion of HLA-DOβ with complex type N-linked glycans, demonstrating
egress from the ER, which is HLA-DOα-dependent (data not shown). 
FACS and confocal analysis
For FACS analysis, cells were stained with saturating amounts of
unlabelled primary antibody and phycoerythrin-conjugated F(ab′)2
rabbit anti-mouse IgG (H + L; Zymed) and analysed on a FACScan
flow cytometer (Becton Dickinson). For immunofluorescence labelling,
cells were fixed in ice-cold methanol and incubated with various anti-
bodies followed by Texas red-conjugated secondary antibodies (Mole-
cular Probes) in saturating amounts, as described [35]. Confocal
analysis was performed using a 600MRC equipped with an
argon/krypton laser (BioRad). Green fluorescence was detected at λ
520–560 nm after excitation at λ = 488 nm. Texas red fluorescence
was detected at λ > 585 nm after excitation at λ = 568 nm.
Biochemical analyses
To isolate antigen-presenting vesicles containing HLA-DM or HLA-
DM–HLA-DO complexes, FACS-sorted GFP-positive cells were
homogenised and postnuclear supernatant was separated by a
linear 0.6–1.4 M sucrose gradient [36]. The vesicular fractions con-
taining lysosomes were identified by measurement of β-hex-
osaminidase activity [36], and concentrated by dilution of sucrose in
the solution and ultracentrifugation [36]. Lysates of purified MIICs or
transfected cells were prepared in 50 mM Tris-HCl buffer containing
0.5% NP-40, 5 mM EDTA and protease inhibitors pH 8.0, and nuclei
and debris were removed by centrifugation. Western-blotting analy-
sis was used to determine that there were similar quantities of HLA-
DM in the lysates. The association and dissociation rates of
biotinylated peptides from affinity-purified DR3 molecules were mea-
sured essentially as described [16,37]. In brief, for dissociation
analyses of bound biotinylated peptides, DR3 complexes were pre-
loaded with 2 µM biotinylated peptides for 3 days (37°C, pH 4.5) in
binding buffer containing 0.2% NP-40. Excess peptides were
removed by 10-K ultrafiltration (Amicon). The time course of peptide
dissociation was determined during 2 h at 37°C in binding buffer
containing 0.2% NP-40 using 30 nM HLA-DR3–peptide complexes
in the presence or absence of cell lysates (equivalent to 5 × 106
cells) or purified MIIC lysates containing HLA-DO–HLA-DM com-
plexes and an excess of 50 µM unlabeled ApoB(2877–2894)
peptide. Association of biotinylated peptides with HLA-DR3 was
determined by adding 2 µM biotinylated peptides to 30 nM HLA-
DR3–CLIP complexes in binding buffer containing 0.2% NP-40,
pH 4.5, at 37°C. MHC–peptide complexes were immunoprecipi-
tated with immobilised L234 antibody and peptides were detected
via biotinylated streptavidin. The absorbance at 405 nm was mea-
sured by an enzyme-linked immunosorbent assay reader (Multiskan
Plus, Titertek) and non-specific signals (quadruplicates, typically
15% of maximal absorbance) were subtracted from the data.
Immunoprecipitation procedures and western-blot analyses were
performed as previously described [27,38]. 
MHC class II peptide isolation, RP–HPLC, mass spectrometry
and peptide sequencing
Peptides were eluted from purified HLA-DR3 complexes as described
[16,39]. RP–HPLC analysis was performed on a SMART system
equipped with a µRPC C2/C18 SC 2.1/10 column (Pharmacia Biotech):
eluent A, 0.1% trifluoroacetic acid (TFA); eluent B, 70% acetonitrile con-
taining 0.1% TFA; gradient, 0–60% in 60 min; flow rate 50µl/min. Col-
lected fractions were analysed by MALD time-of-flight MS [16] with
100 fmol [Glu] fibrinopeptide B (mass 1570.6 Da) added as an internal
mass calibrant. For amino-acid sequence analysis, peptides were
digested with 50 ng trypsin and reacted with n-succinimidyl-2 (3-pyridyl)
acetate (SPA) to enhance β-ion abundance and facilitate sequence
analysis by tandem MS [29]. Derivatised peptides of the CLIPs were
then fully sequenced by low-energy collision-induced dissociation (CID)
using a Finnigan MAT TSQ7000 tandem triple quadrupole MS [30].
T-cell proliferation assays
For antigen presentation experiments, Mel JuSo cells were suspended
in Iscove’s modified Dulbecco’s medium supplemented with 10%
pooled human serum, irradiated (8000 rad) and seeded in 96-well flat-
bottomed microtiter plates at various cell concentrations, previously
determined to trigger optimal T-cell proliferation (781, 1563 and 3125
cells/well) [33]. As antigens were added, purified hsp65 protein from
Mycobacterium tuberculosis, the HLA-DR3-restricted epitope hsp65
peptide p3–13 or the control HLA-DR1 restricted peptide p411–425,
and 104 T cells from the HLA-DR3-restricted, p3–13 specific T-cell
clone Rp15 1-1 were then added. After 66 h in culture, 1 µCi
[3H]thymidine was added to each well, and 18 h later cells were col-
lected on glass-fibre filter strips and the radioactivity incorporated in
the DNA was assessed by liquid scintillation counting [33]. No effect of
HLA-DOαβ–GFP expression on T-cell proliferation was observed when
Mel JuSo cells were exogeneously labelled with hsp65 p3–13 peptide
(data not shown).
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Figure 6
Antigen-presenting capacity of control and HLA-DOαβ–GFP-
expressing cells for epitope p3–13 from Mycobacterium tuberculosis
hsp65 protein. T-cell proliferation of the hsp65 p3–13 reactive, HLA-
DR3-restricted clone Rp15 1-1 (expressed as the amount of [3H]-
thymidine incorporation in cpm) as a function of the number of antigen-
presenting cells (APC) per well. Mel JuSo cells expressing HLA-
DOαβ–GFP and Mel JuSo cells lacking its expression were cultured in
the presence or absence of purified hsp65 protein as indicated. Data
shown are from a representative experiment performed twice in
quadruple; s.e.m. < 10%. T-cell proliferation in response to Mel JuSo
cells pulsed with HLA-DR1-restricted peptide p411–425 was not
significant. Titration experiments of the number of antigen-presenting
cells or the dose of protein antigen tested showed dose-dependent
effects on T-cell proliferation as expected (data not shown).
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